A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Trial Profile

A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Membranoproliferative glomerulonephritis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 22 Dec 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
    • 22 Feb 2018 According to an Achillion Pharmaceuticals media release, interim data from this study is expected in third quarter of 2018.
    • 14 Nov 2017 According to an Achillion Pharmaceuticals media release, Dr. Tom Barbour is the principal investigator of this study. The trial has currently completed treatment of the first group consisting of two sentinel patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top